Biderra
Pharma and laboratory575544-2026

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarung nach § 130a Abs. 8 bzw. § 130c Abs. 8 SGB V zu patentgeschützten Wirkstoffen-VV93

GWQ ServicePlus AG

Open official TED notice Similar notices

Buyer country

Germany

Publication date

20 August 2026

Biderra sector

Pharma and laboratory

Data source

TED open data

Decision signals

First-pass opportunity review

These signals are calculated from the indexed fields. They help prioritize a review but do not replace eligibility checks in the official procurement documents.

Timing signal
341 days to indexed deadline

10 August 2027

Indexed data completeness
86%

Based on seven decision fields

Official title coverage
7 languages

Preserved from source-supplied versions

Classification signal
33600000

Medical equipment, pharmaceuticals and personal care products

90-day market activity
75 related notices

33 buyers in Germany / Pharma and laboratory

Buyer activity
3 indexed notices

Published by this buyer in the last 90 days

Market context

How this notice compares with the current market

Biderra found 75 pharma and laboratory notices from Germany in its rolling 90-day index. 25% publish an estimated value and 45% include at least one indexed deadline. This notice is currently active according to the deadline fields available in the source feed.

Recent notices

75

Value disclosed

25%

Deadline coverage

45%

Related active opportunities

More pharma and laboratory notices from Germany

View the full market

Official title versions

TED may publish the same notice title in several official languages. Biderra preserves the versions supplied in the source feed.

Spanish

Alemania – Productos farmacéuticos – Abschluss nicht-exklusiver Rabattvereinbarung nach § 130a Abs. 8 bzw. § 130c Abs. 8 SGB V zu patentgeschützten Wirkstoffen-VV93

Dutch

Duitsland – Farmaceutische producten – Abschluss nicht-exklusiver Rabattvereinbarung nach § 130a Abs. 8 bzw. § 130c Abs. 8 SGB V zu patentgeschützten Wirkstoffen-VV93

Polish

Niemcy – Produkty farmaceutyczne – Abschluss nicht-exklusiver Rabattvereinbarung nach § 130a Abs. 8 bzw. § 130c Abs. 8 SGB V zu patentgeschützten Wirkstoffen-VV93

French

Allemagne – Produits pharmaceutiques – Abschluss nicht-exklusiver Rabattvereinbarung nach § 130a Abs. 8 bzw. § 130c Abs. 8 SGB V zu patentgeschützten Wirkstoffen-VV93

German

Deutschland – Arzneimittel – Abschluss nicht-exklusiver Rabattvereinbarung nach § 130a Abs. 8 bzw. § 130c Abs. 8 SGB V zu patentgeschützten Wirkstoffen-VV93

Italian

Germania – Prodotti farmaceutici – Abschluss nicht-exklusiver Rabattvereinbarung nach § 130a Abs. 8 bzw. § 130c Abs. 8 SGB V zu patentgeschützten Wirkstoffen-VV93

English

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarung nach § 130a Abs. 8 bzw. § 130c Abs. 8 SGB V zu patentgeschützten Wirkstoffen-VV93

What Biderra adds

For notice 575544-2026, Biderra has normalized the contracting authority country as Germany, grouped CPV 33600000 under pharma and laboratory, compared the available deadline fields with today, measured field completeness, and preserved 7 source-supplied title versions. The official record remains decisive.